ArticleFrontiers in surgery2026
Hepatectomy outperforms microwave ablation for colorectal cancer liver metastases, with anatomical location affecting ablation outcomes.
Article in Frontiers in surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to compare the clinical efficacy of hepatectomy and microwave ablation (MWA) for colorectal cancer liver metastases (CRLM), and to further clarify the clinical value and limitations of MWA in the treatment of high-risk CRLM lesions. Methods: A total of 98 patients with CRLM treated between July 2008 and February 2019 were retrospectively enrolled. Among them, 31 patients underwent hepatectomy and 67 received MWA. Tumor characteristics and long-term prognosis were compared between the two groups. A total of 105 CRLM lesions were further subgrouped into high-risk location ( Results: Patients treated with hepatectomy achieved significantly better recurrence-free survival (RFS) and overall survival (OS) than those treated with MWA. In the MWA cohort, lesions <3 cm in diameter could be completely ablated regardless of anatomical location. For tumors >3 cm, the complete ablation rate was significantly lower in high-risk lesions than in non-high-risk lesions. Multivariate analysis confirmed that tumor diameter was an independent risk factor for incomplete ablation. Conclusion: Hepatectomy provides superior long-term survival benefits over MWA for patients with CRLM. MWA exhibits unsatisfactory efficacy for high-risk lesions, especially those larger than 3 cm in diameter.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.